ATE98630T1 - Radiohalogenierte verbindungen fuer markierung von spezifischen stellen. - Google Patents

Radiohalogenierte verbindungen fuer markierung von spezifischen stellen.

Info

Publication number
ATE98630T1
ATE98630T1 AT89401557T AT89401557T ATE98630T1 AT E98630 T1 ATE98630 T1 AT E98630T1 AT 89401557 T AT89401557 T AT 89401557T AT 89401557 T AT89401557 T AT 89401557T AT E98630 T1 ATE98630 T1 AT E98630T1
Authority
AT
Austria
Prior art keywords
radiohalogenated
compounds
specific site
antibody
marking specific
Prior art date
Application number
AT89401557T
Other languages
English (en)
Inventor
Daniel James Coughlin
Benjamin A Belinka
Vernon Leon Alvarez
Original Assignee
Cytogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogen Corp filed Critical Cytogen Corp
Application granted granted Critical
Publication of ATE98630T1 publication Critical patent/ATE98630T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
AT89401557T 1988-06-07 1989-06-06 Radiohalogenierte verbindungen fuer markierung von spezifischen stellen. ATE98630T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/203,793 US4966999A (en) 1988-06-07 1988-06-07 Radiohalogenated compounds for site specific labeling
EP89401557A EP0348261B1 (de) 1988-06-07 1989-06-06 Radiohalogenierte Verbindungen für Markierung von spezifischen Stellen

Publications (1)

Publication Number Publication Date
ATE98630T1 true ATE98630T1 (de) 1994-01-15

Family

ID=22755342

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89401557T ATE98630T1 (de) 1988-06-07 1989-06-06 Radiohalogenierte verbindungen fuer markierung von spezifischen stellen.

Country Status (9)

Country Link
US (1) US4966999A (de)
EP (1) EP0348261B1 (de)
JP (1) JPH02504643A (de)
AT (1) ATE98630T1 (de)
AU (1) AU3772889A (de)
CA (1) CA1318615C (de)
DE (1) DE68911397T2 (de)
ES (1) ES2062061T3 (de)
WO (1) WO1989011876A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463080A (en) * 1992-08-27 1995-10-31 Bracco International B.V. 2,4,6-triiodo-1,3-benzenedicarboxylic acid compounds used as radiolabelling reagents
US5424402A (en) * 1993-10-18 1995-06-13 Board Of Trustees Of The University Of Kentucky Non-destructive method for radiolabelling biomolecules by halogenation
US6011021A (en) * 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5856106A (en) * 1995-11-01 1999-01-05 Biotransplant, Inc. Determination of antibody production against administered therapeutic glycoproteins, especially monoclonal antibodies
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6384022B1 (en) 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
TR199802638T2 (xx) 1996-06-17 1999-03-22 Guilford Pharmaceuticals, Inc. Kanser tedavisinde naaladase inhibit�rleri kullan�m�.
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
US5962521A (en) * 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
US5981209A (en) * 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6028216A (en) * 1997-12-31 2000-02-22 Guilford Pharmaceuticals Inc. Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
US6129757A (en) * 1998-05-18 2000-10-10 Scimed Life Systems Implantable members for receiving therapeutically useful compositions
TR200100025T2 (tr) 1998-07-06 2001-12-21 Guilford Pharmaceuticals Inc. Farmasötik bileşikler ve kompozisyonlar olarak faydalı naaladaz inhibitörleri.
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
AU2007333049B2 (en) * 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
WO2008121407A1 (en) * 2007-03-30 2008-10-09 The Regents Of The University Of California In vivo imaging of sulfotransferases
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8637640B2 (en) * 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
EP3954394A1 (de) * 2015-06-19 2022-02-16 Centurion BioPharma Corporation Abgabesystem zur kontrollierten arzneimittelfreisetzung
CN111712263B (zh) 2017-11-30 2024-12-17 拉德克斯公司 基于美登木素生物碱的药物递送系统
DK3717503T3 (da) 2017-11-30 2024-01-22 Ladrx Corp Albumin-bindende prodrugs af auristatin E derivater

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2808416A (en) * 1954-08-23 1957-10-01 Eastman Kodak Co Hydrazides of benzoic acid and derivatives thereof as antioxidants for fats and oils
US3809721A (en) * 1970-12-23 1974-05-07 Merck & Co Inc Substituted 2-aminomethyl-4,6-disubstituted phenols
DE2260933C3 (de) * 1972-12-08 1981-08-20 Schering Ag Berlin Und Bergkamen, 1000 Berlin Verfahren zur Herstellung von durch radioaktives Halogen markierten organischen Verbindungen
US3979506A (en) * 1974-10-11 1976-09-07 Pierce Chemical Company Radioactive compounds for labeling proteins
US4474746A (en) * 1980-08-08 1984-10-02 State University Of New York Diagnostic radiopharmaceuticals for localization in target tissues exhibiting a regional pH shift relative to surrounding tissues
US4450149A (en) * 1981-06-15 1984-05-22 Research Corporation Radiohalogenation method
US4430319A (en) * 1982-05-21 1984-02-07 State University Of New York Radioactive iodine labeled phenolic amines
EP0203764B1 (de) * 1985-05-17 1993-03-24 Neorx Corporation Radiohalogenierte kleine Moleküle für das Markieren von Proteinen
US4764598A (en) * 1985-08-22 1988-08-16 The United States Of America As Represented By The Department Of Energy Precursors to radiopharmaceutical agents for tissue imaging

Also Published As

Publication number Publication date
US4966999A (en) 1990-10-30
AU3772889A (en) 1990-01-05
JPH02504643A (ja) 1990-12-27
EP0348261A1 (de) 1989-12-27
EP0348261B1 (de) 1993-12-15
ES2062061T3 (es) 1994-12-16
WO1989011876A1 (en) 1989-12-14
CA1318615C (en) 1993-06-01
DE68911397T2 (de) 1994-05-26
DE68911397D1 (de) 1994-01-27

Similar Documents

Publication Publication Date Title
DE68911397D1 (de) Radiohalogenierte Verbindungen für Markierung von spezifischen Stellen.
FI852974A0 (fi) Nya n-hydroxylgruppen skyddande grupper och framstaellningsfoerfarande foer 3-acylamino-1-hydroxi-2-azetidinoner.
ATE126232T1 (de) Neue derivate von a-nor-3-carboxysteroiden.
DE3586313D1 (de) Konjugate von pharmazeutisch nuetzlichen proteinen.
FI885361A7 (fi) Lääkeaine-monoklonaaliset vasta-aine-konjugaatit
NO178189C (no) Tetrazolmellomprodukter
KR880701379A (ko) 전기 화학 발광 분석법
IT7948485A0 (it) Analisi di prossimita' per scintillazione
ATE103085T1 (de) Erweiterte gleitkommaoperationen zur unterstuetzung der emulation von quellbefehlsausfuehrungen.
FI883383A7 (fi) Apuainekoostumus lannoitteita varten ja sen käyttö
DK156388D0 (da) Skaalmoelledrev
FI863849A7 (fi) Liimakoostumusten valmistus mineraalikuituhuopia varten.
FI885471A7 (fi) Liimakoostumus
IT8420358A0 (it) Procedimento di preparazione di derivati 1-carbamoilmetilici di 4-idrossi-2-osso-pirrolidina nonche' di intermedi per ottenere tali composti.
ATE79373T1 (de) Beta-alkylmelatonine.
PT80268B (pt) Agulha de via ferrea
FI880868A7 (fi) Välituotteina käyttökelpoisia tetratsoliyhdisteitä
NO168962C (no) Retningsstyrt bor
ATE61375T1 (de) Immunogenische konjugate und ihre verwendung in einer dihydropyridinprobe.
IT1223136B (it) Anticorpi monoclonali capaci di legarsi selettivamente alla doxorubicina ed analoghi e derivati
DE3877015D1 (de) Antikoerper enthaltende stabilisierte waesserige zusammensetzung.
FR2563968B3 (fr) Manchon de consolidation de piquets de vignes
IT1202498B (it) Coltura di antera di pomodoro
BG41128A3 (en) Method for prepparing intermediary compounds for preparation of benzothiazine- carboxamides
ES2063890T3 (es) Derivados y analogos de monoetilglicinaxilidina y su produccion y uso.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee